Zacks Investment Research
27 Jul 2026, 17:46 UTC · 2h ago
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
27 Jul 2026, 17:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Medpace (MEDP) is projected to have an EPS growth of 13.5% this year, exceeding the industry average of 12.8%. — Outperforming industry averages in earnings growth is a positive catalyst for individual stock price appreciation.
+0.30Medpace currently reports a year-over-year cash flow growth of 10.5%. — Positive cash flow growth reduces reliance on external funding and supports business expansion.
+0.20Medpace carries a top Zacks Rank and a favorable Growth Style Score. — Positive analyst ratings from a known research provider can increase investor interest, though impact is secondary to fundamental data.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is explicitly recommended by Zacks with a top rank, favorable growth score, and projected earnings growth that exceeds the industry average.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
